Development and in vitro characterization of chitosan-coated polymeric nanoparticles for oral delivery and sustained release of the immunosuppressant drug mycophenolate mofetil

References

• Carmona M, Álvarez M, Marco J, et al. Global organ transplant activities in 2015. Data from the Global Observatory on Donation and Transplantation (GODT). Transplantation. 2017;101:S29.
   Web of Science ®Google Scholar
• Dew MA, DiMartini AF, De Vito Dabbs A, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83:858–873.
   PubMed Web of Science ®Google Scholar
• Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004;77:769–776.
   PubMed Web of Science ®Google Scholar
• Muduma G, Shupo F, Dam S, et al. Patient survey to identify reasons for non-adherence and elicitation of quality of life concepts associated with immunosuppressant therapy in kidney transplant recipients. Patient Prefer Adherence. 2016;10:27.
   PubMed Web of Science ®Google Scholar
• He X, Smeets RL, Koenen HJPM, et al. Mycophenolic acid-mediated suppression of human cd4+ t cells: more than mere guanine nucleotide deprivation. Am J Transplant. 2011; 11:439–449.
   PubMed Web of Science ®Google Scholar
• Fujiyama N, Miura M, Kato S, et al. Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos. 2010;38:2210–2217.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Colombo D, Novara M, et al. Gastrointestinal symptoms impair quality of life in Italian renal transplant recipients but are under-recognized by physicians. Transplant Int. 2010;23:1126–1134.
   PubMed Web of Science ®Google Scholar
• Davies NM, Grinyo J, Heading R, et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant. 2007;22:2440–2448.
   PubMed Web of Science ®Google Scholar
• Shirali AC, Look M, Du W, et al. Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival. Am J Transplant. 2011;11:2582–2592.
   PubMed Web of Science ®Google Scholar
• US provisional patent application 62/640,867 filed Mar 9/18.
   Google Scholar
• Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 2003;86:33–48.
   PubMed Web of Science ®Google Scholar
• Damgé C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release. 2007;117:163–170.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Pandey R, Sharma S, et al. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci. 2006;48:171–176.
   PubMedGoogle Scholar
• Budhian A, Siegel SJ, Winey KI. Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol. J Microencapsul. 2005;22:773–785.
   PubMed Web of Science ®Google Scholar
• Gomezgaete C, Tsapis N, Besnard M, et al. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm. 2007;331:153–159.
   PubMedGoogle Scholar
• Cheng Q, Feng J, Chen J, et al. Brain transport of neurotoxin-I with PLA nanoparticles through intranasal administration in rats: a microdialysis study. Biopharm Drug Dispos. 2008;29:431–439.
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B. 2010;75:1–18.
   PubMed Web of Science ®Google Scholar
• Palacio J, Agudelo NA, Lopez BL. PEGylation of PLA nanoparticles to improve mucus-penetration and colloidal stability for oral delivery systems. Curr Opin Chem Eng. 2016;11:14–19.
   Web of Science ®Google Scholar
• Mohammed M, Syeda J, Wasan K, et al. An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics. 2017;9:53.
   PubMed Web of Science ®Google Scholar
• Chakravarthi SS, Robinson DH. Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm. 2011;409:111–120.
   PubMed Web of Science ®Google Scholar
• Manca ML, Loy G, Zaru M, et al. Release of rifampicin from chitosan, PLGA and chitosan-coated PLGA microparticles. Colloids Surf. B. 2008;67:166–170.
   PubMed Web of Science ®Google Scholar
• Lee BK, Yun Y, Park K. PLA micro- and nano-particles. Adv Drug Deliv Rev. 2016;107:176–191.
   PubMed Web of Science ®Google Scholar
• John J, Sangeetha D, Gomathi T. Sunitinib loaded chitosan nanoparticles formulation and its evaluation. Int J Biol Macromol. 2016;82:952–958.
   PubMed Web of Science ®Google Scholar
• Diop M, Auberval N, Viciglio A, et al. Design, characterisation, and bioefficiency of insulin – chitosan nanoparticles after stabilisation by freeze-drying or cross-linking. Int J Pharm. 2015;491:402–408.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhang Y, Feng J, et al. Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4. Int J Nanomed. 2013;8:1141–1154.
   PubMed Web of Science ®Google Scholar
• Miladi K, Sfar S, Fessi H, et al. Enhancement of alendronate encapsulation in chitosan nanoparticles. J Drug Deliv Sci Technol. 2015;30:391–396.
   Web of Science ®Google Scholar
• Yang H-C, Hon M-H. The effect of the molecular weight of chitosan nanoparticles and its application on drug delivery. Microchem J. 2009;92:87–91.
   Web of Science ®Google Scholar
• Sharma N, Madan P, Lin S. Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: a co-surfactant study. Asian J Pharm Sci. 2016;11:404–416.
   Web of Science ®Google Scholar
• Vila A, Sánchez A, Tobı́o M, et al. Design of biodegradable partilces for protein delivery. J Control Release. 2002;78:15–24.
   PubMed Web of Science ®Google Scholar
• Mainardes RM, Evangelista RC. Praziquantel-loaded PLGA nanoparticles: preparation and characterization. J Microencapsul. 2005;22:13–24.
   PubMed Web of Science ®Google Scholar
• Mu L, Feng SS. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res. 2003;20:1864–1872.
   PubMed Web of Science ®Google Scholar
• Venkatesh DN, Baskaran M, Karri VVSR, et al. Fabrication and in vivo evaluation of Nelfinavir loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic effect. Saudi Pharm J. 2015;23:667–674.
   PubMed Web of Science ®Google Scholar
• Hecq J, Siepmann F, Siepmann J, et al. Development and evaluation of chitosan and chitosan derivative nanoparticles containing insulin for oral administration. Drug Dev Ind Pharm. 2015;41:2037–2044.
   PubMed Web of Science ®Google Scholar
• Patel RR, Chaurasia S, Khan G, et al. Cromolyn sodium encapsulated PLGA nanoparticles: An attempt to improve intestinal permeation. Int J Biol Macromol. 2016;83:249–258.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Thongborisute J, Matsui Y, et al. Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv Drug Deliv Rev. 2005;57:1583–1594.
   PubMed Web of Science ®Google Scholar
• El-Say KM, El-Sawy HS. Polymeric nanoparticles: promising platform for drug delivery. Int J Pharm. 2017;528:675–691.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tan S, Feng S-S. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials. 2012;33:4889–4906.
   PubMed Web of Science ®Google Scholar
• Khan TA, Peh KK, Ch'ng HS. Reporting degree of deacetylation values of chitosan: the influence of analytical methods. J Pharm Pharm Sci. 2002;5:205–212.
   PubMed Web of Science ®Google Scholar
• Curotto E, Aros F. Quantitative determination of chitosan and the percentage of free amino groups. Anal Biochem. 1993;211:240–241.
   PubMed Web of Science ®Google Scholar
• Lubben IM, Van Der Verhoef JC, et al. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci. 2001;14:201–207.
   PubMed Web of Science ®Google Scholar
• Fonte P, Reis S, Sarmento B. Facts and evidences on the lyophilization of polymeric nanoparticles for drug delivery. J. Control Release. 2016;225:75–86.
   PubMed Web of Science ®Google Scholar
• Almalik A, Alradwan I, Kalam MA, et al. Effect of cryoprotection on particle size stability and preservation of chitosan nanoparticles with and without hyaluronate or alginate coating. Saudi Pharm J. 2017;25:861–867.
   PubMed Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Stainmesse S, et al. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58:1688–1713.
   PubMed Web of Science ®Google Scholar
• Félix Lanao RP, Jonker AM, Wolke JGC, et al. Physicochemical properties and applications of poly(lactic-co-glycolic acid) for use in bone regeneration. Tissue Eng Part B. 2013;19:380–390.
   PubMed Web of Science ®Google Scholar
• Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (plga) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3:1377–1397.
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505–522.
   PubMed Web of Science ®Google Scholar
• Mogi T, Ohtake N, Yoshida M, et al. Sustained release of 17β-estradiol from poly (lactide-co-glycolide) microspheres in vitro and in vivo. Colloids Surf. B. 2000;17:153–165.
   Web of Science ®Google Scholar
• Mittal G, Sahana DK, Bhardwaj V, et al. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release. 2007;119:77–85.
   PubMed Web of Science ®Google Scholar
• Pamula E, Menaszek E. In vitro and in vivo degradation of poly(l-lactide-co-glycolide) films and scaffolds. J Mater Sci: Mater Med. 2008;19:2063–2070.
   PubMed Web of Science ®Google Scholar
• Alexis F. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)]. Polym Int. 2005;54:36–46.
   Web of Science ®Google Scholar
• Kumar MNVR, Muzzarelli RAA, Muzzarelli C, et al. Chitosan chemistry and pharmaceutical perspectives. Chem Rev. 2004;104:6017–6084.
   PubMed Web of Science ®Google Scholar